Liquid Array Protein Assay Platform

液阵蛋白检测平台

• 批准号: 7482023
• 负责人: DAVID M ROTHWARF
• 金额: $ 10万
• 依托单位: ARRAYOMICS, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-03-01 至 2009-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7482023
• 关键词: Allergic; Antibodies; Base Pair Mismatch; Binding; Biological Assay; Biomedical Research; Clinical; Code; Communicable Diseases; DNA; Detection; Development; Diagnosis; Diagnostic; Disease; Dose; Foundations; Grant; HIV; Heart Diseases; Kidney Diseases; Liquid substance; Liver diseases; Magnetism; Malignant Neoplasms; Marketing; Methods; Numbers; Phase; Pliability; Process; Protein Analysis; Protein Array; Protein Array Analysis; Protein Microarray Assay; Proteins; Proteomics; Public Health; Range; Research; Rheumatoid Arthritis; Sampling; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Standards of Weights and Measures; System; Technology; United States National Institutes of Health; Work; base; cost; cytokine; design; magnetic beads; novel; outcome forecast; particle; research study; resilience; response; tool; two-dimensional

DESCRIPTION (provided by applicant): The aim of this project is to extend application of a novel `liquid array' platform, based on Encoded Sortable Particle (ESP) technology, into the protein assay realm. ESPs are optically-encoded microfabricated particles that can be manipulated using magnetic force. We will adapt our ESP-based liquid array system, which has already been successfully applied in the DNA space, to incorporate antibody-based protein detection assays in Phase I, and we will extend the scope of protein assay coverage in Phase II. Phase I will consist of a 6-plex cytokine detection analysis, while Phase II is intended to accommodate assays of 1000-plex or more. In the protein space the ESP platform has significant advantages in cost, throughput, scalability, ease of use, and flexibility over existing bead-based liquid array and fixed array platforms. ESP technology has broad applicability and should be a valuable tool in the diagnosis, prognosis, and characterization of a variety of disease states, including cancer, heart disease, arthritis and inflammatory diseases, kidney disease, liver disease, allergic responses, and infectious diseases (e.g. HIV). PUBLIC HEALTH RELEVANCE: ESP technology as applied to the protein assay space will provide a broad platform for many different kinds of assays. The ESP platform is intrinsically versatile, and has the potential to be used in basic biomedical research, as well as high-throughput discovery and clinical diagnostics. The ability to control the particles magnetically (in a manner significantly different from magnetic beads) is a significant advantage. This technology should be useful in the diagnosis and prognosis of a variety of disease states, including cancer, heart disease, arthritis and inflammatory diseases, kidney disease, and infectious diseases (e.g. HIV).

描述(申请人提供)：该项目的目的是将一种基于编码可分类粒子(ESP)技术的新型“液体阵列”平台的应用扩展到蛋白质分析领域。ESP是一种光学编码的微细加工颗粒，可以使用磁力进行操纵。我们将采用我们已经成功应用于DNA领域的基于ESP的液体阵列系统，将基于抗体的蛋白质检测分析纳入第一阶段，我们将在第二阶段扩大蛋白质检测的范围。第一阶段将包括6-plex细胞因子检测分析，而第二阶段旨在适应1000-plex或更多的分析。在蛋白质领域，与现有的基于微珠的液体阵列和固定阵列平台相比，ESP平台在成本、吞吐量、可扩展性、易用性和灵活性方面具有显著优势。ESP技术具有广泛的适用性，应该是一种有价值的工具，用于各种疾病状态的诊断、预后和表征，包括癌症、心脏病、关节炎和炎症性疾病、肾脏疾病、肝脏疾病、过敏反应和传染病(如艾滋病毒)。 公共卫生相关性：将电除尘器技术应用于蛋白质分析领域，将为许多不同类型的分析提供一个广泛的平台。ESP平台本质上是多功能的，具有在基础生物医学研究以及高通量发现和临床诊断中使用的潜力。能够磁性地控制颗粒(以与磁珠显著不同的方式)是一个显著的优势。这项技术应该有助于各种疾病状态的诊断和预后，包括癌症、心脏病、关节炎和炎症性疾病、肾脏疾病和传染病(如艾滋病毒)。